Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205653 | 0.88 | PKM (0.33) | — | |
| SCHEMBL26205652 | 0.86 | SMN1; SMN2 (0.32) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26205632 | 0.80 | SMN1; SMN2 (0.36) | CYP1A2MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30169465 | 0.79 | AAK1 (0.47) | PTGER1 | |
| SCHEMBL26205636 | 0.79 | CYP1A2 (0.35) | CYP1A2SCN4A | |
| SCHEMBL26205643 | 0.78 | GPR88 (0.35) | CYP1A2KDM4EMETKDR | |
| SCHEMBL26205638 | 0.78 | AAK1 (0.39) | MEN1KMT2A | |
| SCHEMBL26205648 | 0.78 | GRM2 (0.35) | PTGER1CYP1A2SMN1; SMN2KDM4E | |
| SCHEMBL27015309 | 0.77 | PTGER1 (0.34) | PTGER1MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL26205634 | 0.75 | KMT2A (0.39) | CYP1A2MEN1KMT2ASMN1; SMN2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | PTGER1 2776/4885CYP1A2 486/4885MEN1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.